Arch Biopartners Doses First Patient in LSALT Peptide Trial
Arch Biopartners has dosed the first patient at Toronto General Hospital in its Phase 2 trial of LSALT peptide...
Arch Biopartners has dosed the first patient at Toronto General Hospital in its Phase 2 trial of LSALT peptide...
Praxis Precision Medicines announced positive topline data from the Phase 2 RADIANT study of vormatrigine in focal onset seizures....
Artelo Biosciences has received positive scientific advice from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its...
Orchestra BioMed (OBIO) has secured $70 million in new funding from Ligand Pharmaceuticals and existing partner Medtronic, bolstering its...
Supernus Pharmaceuticals has completed its acquisition of Sage Therapeutics. The deal brings Sage’s recently approved postpartum depression (PPD) drug,...
Myriad Genetics secured a five-year, $200 million senior secured term loan from OrbiMed, replacing its previous asset-based lending (ABL)...
The FDA has signaled its acceptance of PolTREG’s existing clinical data in Stage 3 Type 1 diabetes (T1D) as...
BriaCell Therapeutics has added UCLA Health Jonsson Comprehensive Cancer Center as a clinical site for its ongoing Phase 3...
Real-world data from 178 early Alzheimer’s disease (AD) patients treated with lecanemab show an 87.4% treatment continuation rate at...
The FDA has cleared Trethera Corporation to initiate a clinical trial evaluating TRE-515 in healthy volunteers. This trial will...